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Abstract
Background: Spinocerebellar ataxia type 8 (SCA8) involves the expression of an expanded CTG/
CAG combined repeats (CR) from opposite strands producing CUG expansion transcripts (ataxin
8 opposite strand, ATXN8OS) and a polyglutamine expansion protein (ataxin 8, ATXN8). The
pathogenesis of SCA8 is complex and the spectrum of clinical presentations is broad.
Results: Using stably induced cell models expressing 0, 23, 88 and 157 CR, we study the role of
ATXN8OS transcripts in SCA8 pathogenesis. In the absence of doxycycline, the stable ATXN8OS
CR cell lines exhibit low levels of ATXN8OS expression and a repeat length-related increase in
staurosporine sensitivity and in the number of annexin positive cells. A repeat length-dependent
repression of ATXN8OS expression was also notable. Addition of doxycycline leads to 25~50
times more ATXN8OS RNA expression with a repeat length-dependent increase in fold of
ATXN8OS RNA induction. ChIP-PCR assay using anti-dimethyl-histone H3-K9 and anti-acetyl-
histone H3-K14 antibodies revealed increased H3-K9 dimethylation and reduced H3-K14
acetylation around the ATXN8OS cDNA gene in 157 CR line. The repeat length-dependent
increase in induction fold is probably due to the increased RNA stability as demonstrated by
monitoring ATXN8OS RNA decay in cells treated with the transcriptional inhibitor, actinomycin
D. In cells stably expressing ATXN8OS, RNA FISH experiments further revealed ribonuclear foci
formation in cells carrying expanded 88 and 157 CR.
Conclusion: The present study demonstrates that the expanded CUG-repeat tracts are toxic to
human cells and may affect ATXN8OS RNA expression and stability through epigenetic and post-
transcriptional mechanisms.
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Background
Spinocerebellar ataxia type 8 (SCA8) is a dominantly
inherited, slowly progressive neurodegenerative disorder
caused by the expansion of CTA/CTG combined repeats
(CR) in the ataxin 8 opposite strand (ATXN8OS) gene
located on chromosome 13q21 [1]. The reported repeat
lengths associated with ataxia vary dramatically, ranging
from 68 [2] to >1000 repeats [3]. In the general popula-
tion more than 99% of the alleles have 16~37 CR [1].
Nevertheless the penetrance of the SCA8 repeat expansion
and ataxia is not complete, as expansions do not always
segregate with ataxia in families and they are present in
rare instances in normal and non-ataxic diseased popula-
tions [1,3-7].
The pathogenesis of SCA8 is complex. In addition to a
CTG repeat expansion in the ATXN8OS gene, it also
involves a CAG repeat expansion in another overlapping
gene, ataxin 8 (ATXN8) [8]. In the CTG direction,
ATXN8OS expresses non-coding transcripts containing
the CUG expansion which overlap with the 5' region of
the Kelch-like 1 (KLHL1) transcripts, and in the CAG
direction ATXN8 expresses transcripts encoding a nearly
pure polyglutamine expansion protein. As a consequence,
three plausible mechanisms were proposed for SCA8:
RNA gain-of function [9], partial loss of KLHL1 function
[10] and polyglutamine expansion protein in the CAG
direction [11]. In the present study, we focus on the RNA
gain-of function mechanism.
The causative agent for myotonic dystrophy (DM1) is also
known to be a CTG expansion in the 3'-UTR of the DMPK
gene [12]. The expanded CUG repeat in the DMPK RNA
impaired nuclear cytoplasmic transport, resulting in
nuclear retention and ribonuclear foci formation [13,14].
In addition, expanded CTG repeats in DM1 alter the adja-
cent chromatin structure [15] and several proteins bind to
CUG repeat-containing RNA [16,17]. Using PC12 neuro-
nal cells expressing the CUG repeat-bearing mRNA, cis-
effects through the reporter gene and neuronal death after
cell differentiation in vitro were reported [18]. Expression
of a Huntington's disease-like 2 JPH3 transcript with an
expanded CUG repeat also resulted in the formation of
RNA foci and cell toxicity [19]. Based on these previous
studies, we established ATXN8OS stably induced HEK-
293 cell lines carrying 0, 23, 88 and 157 CR to investigate
the possible epigenetic and post-transcriptional regula-
tions of the ATXN8OS expression.
Results
ATXN8OS CR cell lines
The pcDNA5/FRT/TO vector and ATXN8OS constructs
containing 0, 23, 88 and 157 CR were used to generate
ATXN8OS CR cell lines. These cell lines were originated
from human embryonic kidney 293 cells, which express
many neuron-specific mRNAs [20]. A large body of work
on other repeat expansion diseases with similar neuronal
pathology using this cell line has been reported [21,22].
The derived ATXN8OS cell lines are isogenic except for the
number of CTA/CTG combined repeats. The repeat
number in these cell lines was stable (data not shown).
ATXN8OS RNA levels were measured by real-time PCR
quantification using ATXN8OS-specific probe and prim-
ers. The expression of the endogenous ATXN8OS RNA in
vector only cell line was too low to be efficiently detected.
In the absence of doxycycline, all ATXN8OS CR cell lines
expressed low level of ATXN8OS RNA, ranging from
0.017 to 0.042 compared with endogenous HPRT1 (Fig.
1C). A repeat length-dependent repression of ATXN8OS
expression is notable. ATXN8OS 88 and 157 CR cells were
more sensitive to staurosporine (30 and 50 nM), an exter-
nal apoptotic stimulus (Fig. 1D). A repeat length related
increase in the number of annexin V-positive cells was
also observed when the viability of these ATXN8OS CR
cell lines was examined. Annexin V binds phosphatidyl
serine (PS) located in the plasma membrane. PS is only
accessible to annexin V during apoptosis when the PS
moves from the inner to the outer plasma membrane, or
during necrosis when membrane integrity is lost. In CR
cells grown without doxycycline, while the absolute level
of cell death was relatively modest, in 88 and 157 CR the
number of dying cells was statistically significant amount-
ing to ~3 times that seen in the cells with 23 CR (Fig. 1E,
– Dox). In CR cells grown with doxycycline, cell death was
also significantly increased, amounting to ~2 times that
seen in the cells with 23 CR (Fig. 1E, + Dox).
Repeat length-related change in ATXN8OS expression The
induction of ATXN8OS RNA levels were further examined
in these CR cells (Fig. 2). After induction with doxycycline
for 1 and 2 days, the amount of ATXN8OS RNA in 0, 23,
88 and 157 CR cells increased significantly. When the
amount of ATXN8OS RNA present at the time of doxycy-
cline addition was set to 100% for each CR cell line, the
fold of induction increased with repeat length, with
(CR)n/fold of induction being (CR)0/29~32, (CR)23/
25~27, (CR)88/41~42, and (CR)157/47~50.
Involvement of reduced ATXN8OS expression with histone 
modification
The expression of the ATXN8OS in 0, 23, 88 and 157 CR
lines was driven by the same hybrid CMV/TetO2 pro-
moter. As CUG triplet repeat expansion in DM1 may alter
the adjacent chromatin structure [15], the observed repeat
length-dependent repression of ATXN8OS expression
may be due to chromatin remodeling. Modifications of
the H3 have been shown to induce a change in chromatin
activity [23]. To examine the possibility that site-specific
H3 modifications might regulate ATXN8OS expression
with CUG repeat expansions, ChIP-PCR analysis was per-
formed using primary antibodies anti-dimethyl-H3-K9
(associated with transcriptionally repressed chromatin)BMC Molecular Biology 2009, 10:9 http://www.biomedcentral.com/1471-2199/10/9
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and anti-acetyl-H3-K14 (associated with transcriptionally
active chromatin). The methylation of H3-K9 in 157 CR
cells was evident, but not in 23 or 88 CR cells (Fig. 3A).
Also hypoacetylation of H3-K14 was observed in 157 CR
cells, but not in 23 or 88 CR cells (Fig. 3B).
Repeat length-dependent repression of HaloTag gene 
located next to ATXN8OS cDNA gene
The cloning vector used to generate ATXN8OS CR lines
was modified by placing a HaloTag gene downstream of
the ATXN8OS cDNA gene. If chromatin structure was
affected in expanded CR lines, reduced expression of
HaloTag would be expected. To examine this, HaloTag
RNA level relative to endogenous HPRT1 RNA was first
quantified by real-time PCR. As shown in Fig. 4A, HaloTag
RNA expression in expanded 88 and 157 CR lines was sig-
nificantly reduced to 70~71% when compared to the nor-
mal 23 CR line (P < 0.05). To confirm the expression
change, proteins were collected and subjected to western
blotting with HaloTag and β-actin antibodies. Consistent
ATXN8OS 0~157 CR cells Figure 1
ATXN8OS 0~157 CR cells. (A) The ATXN8OS cDNA containing exons D, C2, C1, B and A. The combined repeats (CR)n 
inside exon A are indicated. The thick black line below cDNA represents a 213-bp fragment spanning exons B to A for ChIP-
PCR. (B) The features of pcDNA5/FRT/TO-ATXN8OS plasmids. ATXN8OS cDNA was cloned into the NotI site of the 
pcDNA5/FRT/TO vector and its expression driven by hybrid CMV/TetO2 promoter (PCMV 2X TetO2). Also shown is the frag-
ment containing CMV promoter, HaloTag open reading frame and SV40 late poly(A) signal placed at the PvuII site between 
bovine growth hormone poly(A) signal and Flp recombination target (FRT) site. (C) Real-time PCR quantification of ATXN8OS 
RNA level relative to endogenous HPRT1 RNA in ATXN8OS CR cells grown without doxycycline. (D) The effect of 0 nM 
(white bar), 15 nM (gray bar), 30 nM (charcoal gray bar) and 50 nM (black bar) staurosporine on the survival of ATXN8OS 23, 
88 and 157 CR cells grown without doxycycline. (E) Annexin V binding in ATXN8OS 0, 23, 88 and 157 CR cells grown with 
(right) or without (left) doxycycline. Data are represented as the mean ± SD of three independent experiments, each per-
formed in duplicate. The * indicates the difference between the indicated samples are statistically significant (P < 0.05).BMC Molecular Biology 2009, 10:9 http://www.biomedcentral.com/1471-2199/10/9
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Expression of ATXN8OS RNA in 0~157 CR and vector only lines Figure 2
Expression of ATXN8OS RNA in 0~157 CR and vector only lines. Real-time PCR quantification was performed after 
addition of doxycycline for 0~2 days. To calculate the fold of induction, the relative ATXN8OS RNA levels in each CR line at 
the time of doxycycline addition (0 d) are set as 1.0. Data are represented as the mean ± SD of two independent experiments, 
each performed in duplicate.
ATXN8OS CR lines ChIP-PCR assay using anti-dimethyl H3 (K9) and anti-acetyl-histone H3 (K14) antibodies Figure 3
ATXN8OS CR lines ChIP-PCR assay using anti-dimethyl H3 (K9) and anti-acetyl-histone H3 (K14) antibodies. 
ATXN8OS CR cells were sonicated to shear DNA. DNA was then isolated, precipitated with anti-dimethyl H3 (K9) (A) or 
anti-acetyl-histone H3 (K14) (B) antibody, and used as template for PCR amplification of 213-bp exon B to A-containing frag-
ment. Lanes P represents positive control.BMC Molecular Biology 2009, 10:9 http://www.biomedcentral.com/1471-2199/10/9
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with the results of real-time PCR quantification, expres-
sion levels of HaloTag protein were significantly
decreased in ATXN8OS 88 and 157 CR lines as compared
to that of 23 CR line (Fig. 4B, 79~81%, P < 0.05). Fluores-
cence microscope examination after immunocytochemi-
cal staining using HaloTag antibody also revealed the
reduced expression of HaloTag protein (Fig. 4C).
Increased ATXN8OS transcript stability and ribonuclear 
foci formation with CUG repeat expansion
To examine the observed repeat length-dependent
increase of fold of induction, the effect of repeat length on
the stability of ATXN8OS RNA was investigated. The
ATXN8OS cells were grown in the presence of doxycycline
for 48 h and actinomycin D (1 μg/ml) was added to block
transcription of new RNA molecules. The stability of the
ATXN8OS RNA was then determined by real-time PCR
quantification of the amount of ATXN8OS RNA present in
cells harvested at different time points after actinomycin
D addition. The amount of ATXN8OS RNA present at the
start of the experiment immediately before actinomycin D
addition was set to 100%. As shown in Fig. 5A, using
HPRT1 mRNA as an internal control, the levels of
ATXN8OS mRNA at 12 h after addition of actinomycin D
in 23, 88 and 157 CR cells were 7.2%, 12.1% and 22.0%,
respectively. Therefore, expanded CR causes stabilization
of ATXN8OS mRNA and subsequently reduces RNA
decay.
Expression of HaloTag gene located next to ATXN8OS cDNA gene Figure 4
Expression of HaloTag gene located next to ATXN8OS cDNA gene. (A) Real-time PCR quantification of HaloTag 
RNA level relative to endogenous HPRT1 RNA. To normalize, the relative HaloTag RNA in 23 CR cells is set as 1.0. (B) Rep-
resentative western blot image of CR lines using HaloTag and β-actin antibodies. Levels of HaloTag were normalized with an 
internal control (β-actin). The relative immunoreactivity of HaloTag is shown in the right panel. For both (A) and (B), data are 
expressed as the mean ± SEM values from three independent experiments. * indicates P < 0.05. (C) Fluorescence microscopy 
examination after immunostaining using HaloTag antibody (green). Nuclei were counterstained with DAPI (blue).BMC Molecular Biology 2009, 10:9 http://www.biomedcentral.com/1471-2199/10/9
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Since the mutant DMPK and JPH3 transcripts accumu-
lated in the nuclei of patient cells and aggregated to form
distinct foci [13,19], we investigated whether the
expanded ATXN8OS CUG repeats form ribonuclear foci.
The ATXN8OS 23, 88 and 157 CR cells were grown in the
presence of doxycycline and FISH experiments using a
Cy3-labeled (CAG)10  oligonucleotide probe was per-
formed two days later. As shown in Fig. 5B, no ribonuclear
foci were seen in cells expressing ATXN8OS 23 CR. How-
ever, distinct ribonuclear foci, mostly perinuclear, were
observed in cells expressing expanded 88 and 157 CR.
Similar results were obtained using an oligonucleotide
probe specific to ATXN8OS. Since this probe can only
bind to the ATXN8OS RNA in single copy, the inability to
ATXN8OS transcript stability and ribonuclear foci formation with CUG repeat expansion Figure 5
ATXN8OS transcript stability and ribonuclear foci formation with CUG repeat expansion. (A) Real-time PCR 
quantification of ATXN8OS RNA level relative to endogenous HPRT1 RNA following addition of doxycycline for 2 days and 
actinomycin D treatment for 0, 3, 6, 9 or 12 hours. The relative ATXN8OS RNA in 23, 88 and 157 CR cells at the time of 
actinomycine D addition (0 h) is set as 100%. (B) Ribonuclear foci formation with ATXN8OS CUG expansion. ATXN8OS 23, 
88 and 157 CR cells were grown with doxycycline for 2 days and analyzed by RNA-FISH using a Cy3 labeled (CAG)10 (green) 
or Cy5 labeled ATXN8OS unique sequence (red) oligonucleotide probe. Nuclei were counterstained with DAPI (blue).BMC Molecular Biology 2009, 10:9 http://www.biomedcentral.com/1471-2199/10/9
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detect ribonuclear foci with 23 CR is not an artifact of the
copy number of the repeats in the 88 or 157 CR cells.
Discussion
Clinical and genetic studies have shown that SCA8 is a
slowly progressive inherited disorder with highly incom-
plete penetrance, in addition to its rare occurrence of phe-
notype in individuals carrying a much larger repeat
expansion [1,4-7]. Thus the pathogenic mechanisms
underlying SCA8 are expected to be complicated. In this
study we developed a number of otherwise isogenic
human cell lines expressing transcripts with 0~157 CTA/
CTG CR. The repeat number in these cell lines was stable
and expression of ATXN8OS RNA containing expanded
88 and 157 CR causes an increase in the likelihood of cell
death (Fig. 1E). These cells are also sensitive to stau-
rosporine treatment which can induce apoptosis (Fig.
1D). This observation coincides with the reported length-
dependent toxicity of untranslated CUG repeats in cell
and Caenorhabditis elegans experiments [17,19,24]. These
cells were used to investigate the possible epigenetic and
post-transcriptional controls of the ATXN8OS expression.
The implications of the findings in the pathogenesis of
SCA8 are discussed as the following.
Epigenetic changes of ATXN8OS expression
Previously expansions of CTG repeat in myotonic dystro-
phy and GAA repeat in Friedreich's ataxia conferred varie-
gation of expression on a linked transgene in mice [25].
Silencing was correlated with a decrease in promoter
accessibility and was enhanced by the classical position
effect variegation modifier heterochromatin protein 1
(HP1), which is able to bind to methylated histone H3-K9
[26]. Elevated levels of histone H3 dimethylated on K9
were also seen in Friedreich's ataxia cells consistent with a
repressive chromatin organization [27]. The "Histone
Code" hypothesis proposed that amino-terminal exten-
sions of histones are subject to a variety of posttransla-
tional modification [23]. Histone methylation and
acetylation are among the best characterized modifica-
tions to regulate gene expression through alterations in
the chromatin structure. In chromatin domains that are
transcriptionally repressed, high levels of histone H3-K9
methylation and H3-K14 hypoacetylation were observed.
Therefore, it is possible to predict the transcriptional com-
petence of a particular genomic region by examining the
H3 methylation and acetylation patterns. Using ChIP
assay, we provided direct evidence of H3-K9 dimethyla-
tion and H3-K14 hypoacetylation and repression of
ATXN8OS RNA in the 157 CR cells (Fig. 3). As reduced
expression of adjacent HaloTag gene was also seen in the
88 CR cells (Fig. 4) independent of H3-K9 dimethylation
and H3-K14 hypoacetylation (Fig. 3), DNA methylation
or other histone modifications such as arginine methyla-
tion and serine/threonine phosphorylation [28] may be
responsible for the observed repression of ATXN8OS RNA
in the 88 CR cells. Nevertheless the epigenetic change
induced by large SCA8 repeat expansions may be one of
the genetic factors that suppress the disease symptoms in
control individuals carrying large SCA8 repeat expan-
sions. Work is now in progress to examine the roles of
HP1 and its associated regulators on the observed repeat-
dependent repression of ATXN8OS expression.
Increased ATXN8OS transcript stability and ribonuclear 
foci formation
Previously it was reported that expanded CUG repeat tran-
scripts form stable hairpins [29] and muscleblind and
MBNL1 increase steady state levels of CUG repeat RNA
[30]. The possibility of stable hairpin formation and pro-
teins binding may explain the observation that expanded
CR causes stabilization of ATXN8OS mRNA (Fig. 5A), and
in turn leads to repeat length-dependent increase in fold
of ATXN8OS induction (Fig. 2). In DM1 and DM2, the
expanded repeat RNA forms discrete ribonuclear foci to
sequester CUG binding proteins and subsequently jeop-
ardize the normal cellular functions of these proteins,
which would then lead to abnormal RNA splicing of sev-
eral genes [31]. Although the induced expression levels of
ATXN8OS RNA in these CR cells were low (ranging from
0.659~1.346 compared with endogenous HPRT1), ribo-
nuclear foci were detected in our ATXN8OS 88 or 157 CR
cells (Fig. 5B). Most of the RNA foci formed are located
near nuclear membrane, which may be compatible with
the observation by Koch and colleague that the hairpin
structure formed by long CUG repeats (> 44) cannot pass
through nucleic pores [32]. The ribonuclear foci observed
in the nucleus may also result in transcriptional dysfunc-
tion to lead to the disease, as indicated by transcription
factors leaching from chromatin by mutant RNA in myot-
onic dystrophy [33].
Conclusion
In summary, our data provide evidence of epigenetic and
post-transcriptional regulations of the ATXN8OS expres-
sion. Although the in vitro cell culture study may not truly
reflect the pathological events in vivo, our study may shed
insights into the pathogenesis of this disease.
Methods
ATXN8OS cDNA constructs
Human cerebellum polyadenylated RNA (200 ng) (Clon-
tech) was reverse transcribed using the SuperScript™ III
reverse transcriptase (Invitrogen). Sense and antisense
primers used for amplification of ATXN8OS cDNA were
5'-ATCCTTCACCTGTTGCCT-3' and 5'-GCTTGTGAG-
GACTGAGAATG-3', respectively. The 1.3-kb full-length,
23 CR [(CTA)11(CTG)12] containing cDNA (including
exons D, C2, C1, B, and A) (Fig. 1A) [34] was cloned into
pGEM-T Easy vector (Promega) and sequenced. TheBMC Molecular Biology 2009, 10:9 http://www.biomedcentral.com/1471-2199/10/9
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cloned ATXN8OS cDNA containing 88 CR was made by
replacing a 178 bp NlaIII-AflII fragment with a 373 bp
fragment from the PCR clone of a PD patient
[(CTA)8CCACTACTGCTACTGCTA(CTG)74] [35]. The 88
CR was further expanded to 157 CR
[(CTA)8CCACTACTGCTACTGCTA(CTG)67CTA(CTG)65C
TA(CTG)9] by ligating Fnu4HI partially digested frag-
ments. The interruption of the CTG repeat tract by CCA
and CTA is similar to that reported seen in SCA8 patients
[36]. To construct the clone without combined repeats (0
CR), a DraI site was added to the 5' end of CTA/CTG
repeats by site-directed mutagenesis using primer 5'-
CCCTGGGTCCTTCATGTTAGAAAACCTGGCTT-
TAAAA(CTA)8C-3' and a 273-bp DraI fragment contain-
ing 88 CTA/CTG combined repeats was removed. Then
the ATXN8OS cDNA was cloned into the NotI site of
pcDNA5/FRT/TO vector (Invitrogen) for establishing sta-
bly induced ATXN8OS CR cell lines. The pcDNA5/FRT/
TO vector used was modified by inserting a 2.3 kb BglII
(blunted)-FspI fragment containing CMV enhancer/pro-
moter, HaloTag open reading frame and SV40 late
poly(A) signal from pHT2 (Promega) at the PvuII site
between bovine growth hormone poly(A) signal and Flp
recombination target (FRT) site (Fig. 1B).
Cell culture and ATXN8OS CR cell lines
HEK-293-derived Flp-In™-293 (Invitrogen) cells were cul-
tivated in Dulbecco's modified Eagle's medium contain-
ing 10% fetal bovine serum in a 37°C humidified
incubator with a 5% CO2  atmosphere. The cloned
pcDNA5/FRT/TO-ATXN8OS plasmids and vector were
used to generate the ATXN8OS CR and vector only cell
lines by targeting insertion into Flp-In™-293 cells, accord-
ing to the supplier's instructions. The repeats in these
ATXN8OS cell lines were examined by PCR and sequenc-
ing. These cell lines were grown in medium containing 5
μg/ml blasticidin and 100 μg/ml hygromycin. Doxycy-
cline (1 μg/ml) was added to induce ATXN8OS expres-
sion. To evaluate the stability of ATXN8OS transcripts,
actinomycin D (1 μg/ml) (A1410, Sigma) was added 48
hr after induction for 0, 3, 6, 9 and 12 hr for total RNA
preparation.
Real-time PCR quantification of mRNA
Total RNA was extracted from ATXN8OS CR and vector
only cells using the Trizol (Invitrogen). The RNA was
DNase (Stratagene) treated, quantified, and reverse-tran-
scribed to cDNA using High Capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems) with random primers.
Using ABI PRISM®  7000 Sequence Detection System
(Applied Biosystems), real-time quantitative PCR was per-
formed on a cDNA amount equivalent to 250 ng total
RNA with TaqMan fluorogenic probes Hs01382089-m1
(exon C2 and C1 boundary) for ATXN8OS and 4326321E
for HPRT1 (endogenous control) (Applied Biosystems).
The amount of HaloTag mRNA was determined by cus-
tomized Assays-by-Design probe (Forward primer:
CCGACGTGGGACGAATGG, Reverse primer: CGGAAG-
GCCTGGAAGGT, TaqMan® probe: GAATTCGCCCGTGA)
(4331348, Applied Biosystems). Fold change was calcu-
lated using the formula 2ΔCt, ΔCT = CT (control) - CT (tar-
get), in which CT indicates cycle threshold.
Cell viability assay
To quantify the cell viability, mitochondrial dehydroge-
nase activity was evaluated by measuring its cleaving activ-
ity of the tetrazolium salt WST-1 (Takara). The cultured
cell suspension was seeded into a 96-well plate. After stau-
rosporine (0~50 nM) treatment for one day, PreMix WST-
1 was added to cells in a final 1:10 dilution and incubated
for 2 hours. The absorbance of the red colored formazan
dye cleaved from WST-1 was measured at 450 nm by
Microplate Autoreader EL311 (Bio-Tek Instruments Inc.).
Reactions were performed in triplicate. Annexin V-posi-
tive cells were determined using Annexin V-FITC Apopto-
sis Detection Kit (Strong Biotech Corp.) according to the
supplier's instructions. Each cell line was tested at least 3
times and apoptotic cells quantitatively determined by
flow cytometry.
Chromatin immunoprecipitation (ChIP)-PCR
Cells on five 10 cm dishes were incubated with 1% for-
maldehyde for 10 min to cross-link histones to DNA.
Cells were then washed twice using cold PBS containing
protease inhibitors (1 mM phenylmethylsulfonyl fluo-
ride, 1 μg/ml aprotinin and 1 μg/ml pepstain A). The
washed cells were scraped and resuspended in lysis buffer
(1% SDS, 10 mM EDTA, 50 mM Tris pH 8.1) (Upstate
Biotechnology). The resulting lysate was subjected to son-
ication. The sample was centrifuged to remove cell debris.
The volume of the chromatin supernatant was divided
into several parts. The first part was used as input (posi-
tive) control, and other parts were diluted with ChIP dilu-
tion buffer containing protease inhibitors to bring up the
volume to 2 ml. The chromatin solution was incubated
with 75 μl of a mixture of protein A-agarose/salmon
sperm DNA slurry (Upstate Biotechnology) for 30 min at
4°C with agitation to reduce nonspecific background. Fol-
lowing this preclearing procedure, the solution was centri-
fuged and the supernatant was collected. Five micrograms
of anti-dimethyl H3-K9 or anti-acetylated-H3-K14 anti-
body (Upstate Biotechnology) were added to the chroma-
tin solution and incubated overnight at 4°C with
rotation. The resulting immune complexes were collected
by addition of 60 μl of protein A-agarose/salmon sperm
DNA slurry and incubated at 4°C with rotation for 1 h.
The beads were washed several times and the attached
immune complexes were eluted with 250 μl elution buffer
containing 1% SDS and 0.1 M NaHCO3. Cross-links were
reversed by the addition of 8 μl 5 M NaCl and incubatingBMC Molecular Biology 2009, 10:9 http://www.biomedcentral.com/1471-2199/10/9
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the samples at 65°C for 4 hr. The DNA was purified by
phenol/chloroform extraction and analyzed by PCR using
the primer pair specific to the exons B to A region (5'-
CAAACTTCAGAGAGAGAGGG-3' and 5'-CAGAGT-
TAATCTCTCCGTGG-3', 213 bp fragment) of ATXN8OS
cDNA gene (Fig. 1A).
Western blot analysis
ATXN8OS CR cells were lysed in RIPA buffer (10 mM Tris
pH 7.5, 150 mM NaCl, 5 mM EDTA pH 8.0, 0.1% sodium
dodecyl sulphate (SDS), 1% deoxycholate, 1% NP-40)
containing the protease inhibitor mixture (Sigma). After
sonication and sitting on ice for 30 min, the lysates were
centrifuged at 13 000 g for 30 min at 4°C. Protein concen-
trations were determined with the Bio-Rad protein assay
kit, using albumin as standards. Laemmli sample buffer
was then added to 30 μg of protein and heated in a boiling
water bath for 10 min. Equal amounts of protein from
each sample were fractionated in a 12% SDS-polyacryla-
mide gel electrophoresis (PAGE). The fractionated protein
samples were transferred onto a nitrocellulose membrane
(Schleicher and Schuell), and non-specific binding was
blocked in 5% non-fat dry milk for overnight at 4°C. After
washing with Tris-buffered saline (TBS), the blots were
probed with a 1:1000 dilution of HaloTag antibody
(Promega) or a 1:10000 dilution of actin antibody
(Chemicon) in TBS/1% bovine serum albumin/0.1%
Tween 20 for 1 hr at room temperature with gentle shak-
ing. After extensive washing, the blots were probed with a
1:10000 dilution of goat anti-mouse or goat anti-rabbit
IgG conjugated to horseradish peroxidase (Jackson
ImmunoResearch). The blots were washed extensively
and the protein detected using Immobilon™ western
chemiluminescent HRP substrate (Millipore).
Immunocytochemical staining
ATXN8OS CR cells on coverslips were washed with PBS
and fixed in 4% paraformaldehyde in PBS for 10 min, fol-
lowed by 20 min incubation with 0.1% Triton X-100 in
PBS to permeabilize cells, overnight incubation with 0.5%
bovine serum albumin in PBS to block non-specific bind-
ing. The primary anti-HaloTag antibody, diluted 1:500 in
1% BSA in TBS, was used to stain cells at 4°C overnight.
After washing, cells were incubated for 2 hr at room tem-
perature in FITC-conjugated secondary antibody diluted
to 1:500 in TBS containing 1% BSA, and washed in PBS.
Nuclei were detected using 4'-6-diamidino-2-phenylin-
dole (DAPI). The stained cells were examined after
mounted in Vectashield (Vector Laboratories Inc.) using a
Leica TCS confocal laser scanning microscope.
Fluorescent in situ hybridization (FISH)
To examine the ribonuclear foci, cells were grown on cov-
erslips, washed, and fixed for 15 min at room temperature
in 4% formaldehyde and 10% acetic acid. After 0.1% Tri-
ton X-100 treatment for 10 min, a Cy3-(CAG)10 (Operon)
or Cy5-CTGCGACTCCGCTGGAAACTCTTCAGCCA
(unique toATXN8OS) oligonucleotide probe was added
at 37°C for 2 hr for FISH experiments http://www.singer
lab.org/protocols. Nuclei were detected using DAPI (4'-6-
diamidino-2-phenylindole). Fluorescent signals are visu-
alized using a Leica TCS confocal laser scanning micro-
scope optimized for simultaneous dual fluorescent
imaging.
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